Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

17.12
-7.7550-31.18%
Pre-market: 17.530.4150+2.42%05:26 EST
Volume:17.68M
Turnover:315.31M
Market Cap:1.07B
PE:-3.94
High:21.07
Open:20.90
Low:16.21
Close:24.87
52wk High:71.50
52wk Low:7.76
Shares:62.29M
Float Shares:40.64M
Volume Ratio:10.07
T/O Rate:43.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3443
EPS(LYR):-4.9242
ROE:-165.27%
ROA:-13.89%
PB:4.66
PE(LYR):-3.48

Loading ...

RBC Capital says Makary comments on uniQure gene therapy approach disappointing

TIPRANKS
·
14 hours ago

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and uniQure (QURE)

TIPRANKS
·
17 hours ago

Stifel says uniQure ‘understandably’ under pressure on Makary comments

TIPRANKS
·
17 hours ago

Class Action Lawsuit Targets uniQure NV Investors

Reuters
·
Yesterday

Rosen Law Firm Sets April 13 Lead Plaintiff Deadline in uniQure Securities Class Action

Reuters
·
Yesterday

Rosen Law Firm urges uniQure investors to act before April 13 lead plaintiff deadline

Reuters
·
Feb 25

uniQure Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Feb 24

uniQure initiated with a Peer Perform at Wolfe Research

TIPRANKS
·
Feb 24

uniQure NV updated its financial calendar

Reuters
·
Feb 23

uniQure to Announce 2025 Financial Results

GlobeNewswire
·
Feb 23

Class Action Lawsuit Targets uniQure NV Over Alleged Securities Fraud

Reuters
·
Feb 18

Investors Sue uniQure NV Over Alleged Misleading Disclosures

Reuters
·
Feb 17

uniQure Faces Class Action Over Alleged Misleading Statements on Drug Approval

Reuters
·
Feb 14

Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures

Simply Wall St.
·
Feb 12

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 10

How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors

Simply Wall St.
·
Feb 09

Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch

Benzinga_recent_news
·
Feb 07

uniQure präsentiert neue Phase-I/IIa-Daten zur Gentherapie AMT-191 bei Fabry-Krankheit

Reuters
·
Feb 06

uniQure Reports Sustained Enzyme Increases in Phase I/IIa Fabry Disease Gene Therapy Trial

Reuters
·
Feb 06

A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations

Simply Wall St.
·
Feb 04